Recombinant Human Tumor Necrosis Factor Administered as a 24-Hour Intravenous Infusion. A Phase I and Pharmacologic Study

Spriggs, David R.; Sherman, Matthew L.; Michie, Hamish R.; Arthur, K A; Imamura, K; Wilmore, Douglas W.; Frei, Emil; Küfe, Donald

doi:10.1093/jnci/80.13.1039

Cited by 293 publications

(139 citation statements)

References 0 publications

Supporting

Mentioning

135

Contrasting

Unclassified

Order By: Relevance

“…Extrapolating from this earlier experiment, stimulation of LTβR or TNFR expressed by tumor stromal cells may promote the formation of lymphoid-like structures inside the tumor tissues, which in turn may facilitate tumor destruction. Systemic TNFR signaling is of course too toxic, as evidenced by other systemic TNF treatments [34]. Soluble LTα can signal through the TNFR resulting in the upregulation of chemokines.…”

Section: Light Creates Lymphoid-like Tissues Inside the Tumor To Imprmentioning

confidence: 99%

Targeting tumors with LIGHT to generate metastasis-clearing immunity

Yü¹,

Fu²

2008

Cytokine & Growth Factor Reviews

View full text Add to dashboard Cite

Metastastic diseases cause the majority of morbidity and mortality of cancer patients. Established tumors form both physical and immunological barriers to limit immune detection and destruction. Current immunotherapy of vaccination and adoptive transfer shows limited effect at least in part due to the existing barriers in the tumors and depending on the knowledge of tumor antigens. Tumor necrosis factor superfamily member 14 (TNFSF14) LIGHT interacts with stromal cells, dendritic cells, NK cells, naïve and activated T cells and tumor cells inside the tumor tissues via its two functional receptors, HVEM and lymphotoxin β receptor (LTβR). Targeting tumor tissues with LIGHT leads to augmentation of priming, recruitment, and retention of effector cells at tumor sites, directly or indirectly, to induce strong anti-tumor immunity to inhibit the growth of primary tumors as well as eradicate metastases. Intratumor treatment would break tumor barriers and allow strong immunity against various tumors without defining tumor antigens. This review summarizes recent findings to support that LIGHT is a promising candidate for an effective cancer immunotherapy.

show abstract

Section: Light Creates Lymphoid-like Tissues Inside the Tumor To Imprmentioning

confidence: 99%

Targeting tumors with LIGHT to generate metastasis-clearing immunity

Yü¹,

Fu²

2008

Cytokine & Growth Factor Reviews

View full text Add to dashboard Cite

show abstract

“…After the introduction of bacteria or endotoxin into the systemic circulation in animal models, the concentration of TNF␣ increases, and the effects of administration of TNF␣ in humans reproduce the physiologic and chemical changes seen in severe sepsis (15). Furthermore, antibodies directed against TNF␣ have exhibited a protective role in animal models of sepsis (16)(17)(18).…”

Section: Tnf␣ Inhibition and Sepsismentioning

confidence: 99%

Infections and anti–tumor necrosis factor α therapy

Ellerin¹,

Rubin²,

Weinblatt³

2003

Arthritis & Rheumatism

267

125

View full text Add to dashboard Cite

“…58 Soluble LTa can signal through the TNFR resulting in the upregulation of chemokines. To avoid systemic toxic effects, recombinant LTa has been conjugated with a tumor-specific antibody to be delivered specifically to the tumor tissue.…”

Section: Targeted Immunotherapy To Primary Tumor Tissues Can Generatementioning

confidence: 99%

Targeting and utilizing primary tumors as live vaccines: changing strategies

Yang

Mortenson

2011

Cell Mol Immunol

View full text Add to dashboard Cite

Tumor metastases and relapse are the major causes of morbidity and mortality in cancer. Although surgery, chemotherapy and/or radiation therapy can typically control primary tumor growth, metastatic and relapsing tumors are often inaccessible or resistant to these treatments. An adaptive immune response can be generated during these conventional treatments of the primary tumor, and presumably both the primary tumor and secondary metastases share many of the same or similar antigenic characteristics recognized by the immune system. Thus, when established, this response should be able to control metastatic growth and tumor relapse. This review summarizes the mechanisms by which antitumor immune responses are generated, and recent findings supporting the hypothesis that many therapies targeting primary tumors can generate antitumor adaptive immune responses to prevent metastases and tumor relapse. Keywords: chemotherapy; immunotherapy; metastasis; radiotherapy; tumor vaccine INTRODUCTION Conventional treatments such as surgery and chemotherapy are effective means of eliminating or reducing primary tumor growth, but have not proved effective in eradicating metastases. Because metastatic disease may not respond similarly to chemotherapies used in treating the primary tumor, 1 recent research has focused on the importance of generating an antitumor immune response to control metastatic disease. Presumably, both the primary tumor and secondary metastases share many of the same or similar antigenic characteristics recognized by the immune system; yet, there has been no clear strategy formulated in which a patient's own tumor tissues is used to generate an antitumor adaptive immune response for the eradication of metastases and prevention of relapse. Once tumors metastasize, curing the disease is difficult and rare. This review summarizes recent findings supporting the hypothesis that targeting primary tumors with both conventional and new therapies can potentially generate antitumor adaptive immune responses that prevent metastases and relapse.Due to the vast number of genetic changes associated with carcinogenesis, tumors express many neo-antigens and mutated antigens. Indeed, much evidence exists to indicate that many cancers are antigenic and thus recognizable by the adaptive immune system. 2 Mere recognition by adaptive immunity, however, is insufficient, given that these antigenic cancers rarely regress spontaneously. Effective antitumor immunity depends on both the presence of tumor-reactive lymphocyte precursors and means by which these precursor lymphocytes can be activated. Most T cells with high affinity to tissue-specific antigens are deleted in the thymus or later tolerized in the peripheral

show abstract

Recombinant Human Tumor Necrosis Factor Administered as a 24-Hour Intravenous Infusion. A Phase I and Pharmacologic Study

Cited by 293 publications

References 0 publications

Targeting tumors with LIGHT to generate metastasis-clearing immunity

Targeting tumors with LIGHT to generate metastasis-clearing immunity

Infections and anti–tumor necrosis factor α therapy

Targeting and utilizing primary tumors as live vaccines: changing strategies

Contact Info

Product

Resources

About